TB-500 (Thymosin beta-4): Research Profile and Study Landscape

What TB-500 is

TB-500 is a common laboratory name for Thymosin beta-4 (Tβ4), a highly conserved 43-amino-acid peptide encoded by the X-linked TMSB4x gene. As described in a review of its role in kidney disease, Tβ4 is the predominant β-thymosin in mammalian cells and was historically characterised primarily as an actin-sequestering molecule—a protein that binds monomeric actin and thereby participates in cytoskeletal regulation. The same review notes that Tβ4 and its N-terminal metabolite N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) have more recently been studied as broader regulators of cellular homeostasis.

How the research studies it

Thymosin beta-4 has been studied across several distinct research areas, each anchored to a different preclinical model system. In tissue and reconstructive contexts, it has been examined in adipose-derived stem cell (ADSC) and fat-graft systems. In metabolic-liver research it has been studied in a high-fat-diet rat model of non-alcoholic fatty liver disease (NAFLD) alongside palmitic-acid-treated LO2 liver cells. In neuroscience it has been investigated using cerebral organoids derived from induced pluripotent stem cells carrying familial Alzheimer disease mutations, together with 5xfAD model mice. A dedicated review has synthesised its study across models of acute and chronic kidney injury. Taken together, the evidence cited here is predominantly in vitro and animal, with the review noting translational questions that remain open; controlled human data are not represented in this set.

What the strongest research examines

In a fat-graft study, Tβ4 was reported to upregulate the Rac/F-actin pathway and to be associated with increased formation of tunneling nanotubes and mitochondrial transfer from ADSCs to adipocytes and newly formed vessels, a process the authors linked to reduced oxidative stress and apoptosis in that graft model. In the NAFLD work, Tβ4 was associated with altered expression of ferroptosis-related genes and with up-regulation of GPX4 in high-fat-diet rats and palmitic-acid-treated LO2 cells; siRNA knockdown of GPX4 was used to probe this relationship, and a ferroptosis inhibitor was included as a comparator.

In the neuroscience study, TMSB4X expression was reported to be decreased in neurons of familial-AD organoids and in excitatory neurons from Alzheimer patient data, and treatment with Tβ4 was associated with changes in neurodevelopmental deficits and β-amyloid formation in the organoid and 5xfAD mouse models. Across kidney-injury models, the review characterises the Tβ4–Ac-SDKP axis in terms of cytoprotective, anti-inflammatory, and antifibrotic actions, while explicitly noting disparate and bidirectional findings on fibrosis that appear to be model-dependent. These observations are confined to the preclinical systems in which they were made.

What the research does not show

The human evidence identified in this search is limited in scale; larger controlled trials establishing exposure and long-term safety in humans are not yet available.